TABLE 1.
Clinical and phenotypic characteristics of patients with PD‐L1+ and PD‐L1− IVLBCL
| Variables | PD‐L1+ IVLBCL (n = 12) | PD‐L1－ IVLBCL (n = 22) | P |
|---|---|---|---|
| Sex (male/female) | 5/7 | 11/11 | .72 |
| Age, median (range) | 74 (51‐81) | 75 (64‐86) | .036 |
| Age > 60 y | 9/12 (75%) | 22/22 (100) | .037 |
| Performance status > 1 | 8/12 (75%) | 16/21 (76%) | .69 |
| IPI (HI/H) | 10/11 (91%) | 20/21 (95%) | 1.0 |
| Stage III/IV | 11/12 (92%) | 21/21 (100%) | .36 |
| plt < 14 × 104/μL | 9/11 (82%) | 14/21 (67%) | .44 |
| WBC < 3.5 × 103/μL | 4/11 (36%) | 3/21 (14%) | .20 |
| Alb < 3.0 g/dL | 8/11 (73%) | 19/21 (90) | .31 |
| CRP > 1.0 mg/dL | 11/11 (100%) | 20/21 (95%) | 1.0 |
| sIL‐2R > normal | 11/12 (92%) | 21/21 (100%) | .36 |
| LDH > normal | 11/11 (100%) | 20/21 (95%) | 1.0 |
| Hb < 11 | 9/11 (81%) | 15/21 (71%) | .68 |
| B symptoms | 8/12 (67%) | 19/22 (86%) | .21 |
| Hepatomegaly | 1/12 (8.3%) | 4/19 (21%) | .62 |
| Splenomegaly | 7/12 (58%) | 8/19 (42%) | .47 |
| Respiratory symptoms | 1/12 (8.3%) | 10/18 (56%) | .018 |
| CNS symptoms | 6/12 (50%) | 8/19 (42%) | .72 |
| Cutaneous involvement | 9/12 (75%) | 16/22 (55%) | .61 |
| Variant (Classic/HPS) | 2/9 | 1/20 | .27 |
| CD5 positivity | 2/7 (29%) | 8/19 (42%) | .67 |
| COO (GCB/non‐GCB subtype) | 1/6 | 2/15 | 1.0 |
P value with siginificant difference are shown in bold value.
Abbreviations: Alb, albumin; CNS, central nervous system; COO, cell of origin; CRP, C‐reactive protein; GCB, germinal center B cell; H, high; Hb, hemoglobin; HI, high‐intermediate; HPS, hemophagocytic syndrome; IPI, international prognostic index; LDH, lactate dehydrogenase; plt, platelet; sIL‐2R, soluble interleukin‐2 receptor; WBC, white blood cell.